drugset / Trial / NCT05281406
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
NaSingle-groupOpen-labelTreatment
Summary
PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.
Timeline
- Start
- 2021-11-12
- Primary completion
- 2025-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Osimertinib | Small molecule | 40 mg | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |